Editorial: The MASLD spectrum: an emerging epidemic of cardiometabolic and extra-hepatic dimensions - Takeaways - MDSpire

Editorial: The MASLD spectrum: an emerging epidemic of cardiometabolic and extra-hepatic dimensions

  • By

  • Akash Batta

  • Arka De

  • Omesh Goyal

  • Aalam Sohal

  • June 17, 2026

  • 0 min

Share

  • 1

    MASLD is recognized as a multisystem disease with significant cardiometabolic and extra-hepatic implications, including CVD and CKD.

  • 2

    Early identification of high-risk individuals for MASLD is crucial, with the CALLY index serving as a promising non-invasive biomarker.

  • 3

    Sarcopenia is an independent risk factor for MASLD and advanced liver fibrosis, highlighting the need to maintain skeletal muscle mass.

  • 4

    Visceral fat area is more strongly associated with MASLD than traditional BMI, necessitating sex-specific metabolic risk assessments.

  • 5

    Therapeutic strategies for MASLD should focus on integrated care, particularly in managing T2DM and selecting effective anti-diabetic treatments.

Original Source(s)

Editorial: The MASLD spectrum: an emerging epidemic of cardiometabolic and extra-hepatic dimensions

  • by Akash Batta, Arka De, Omesh Goyal, Aalam Sohal

  • June 17, 2026

Related Content

Association between red cell distribution width and HBV viral load and liver function parameters in patients with chronic hepatitis B: a real-world data study

Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor

Case Report: Malignancy-mimicking imaging appearances of hepatic parasitic diseases